AGIOS PHARMACEUTICALS

Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency

18 Aug 2022 15:35:00 By Nasdaq GlobeNewswire

Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors

15 Aug 2022 05:00:00 By Nasdaq GlobeNewswire

Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia

11 Aug 2022 15:35:00 By Nasdaq GlobeNewswire

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer

08 Aug 2022 15:36:08 By Nasdaq GlobeNewswire

Agios Reports Business Highlights and Second Quarter 2022 Financial Results

04 Aug 2022 04:00:02 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022

14 Jul 2022 04:00:00 By Nasdaq GlobeNewswire

Agios Appoints Brian Goff as Chief Executive Officer

12 Jul 2022 13:01:00 By Nasdaq GlobeNewswire

Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress

10 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Agios Announces Evolution of Research Organization

16 May 2022 13:15:00 By Nasdaq GlobeNewswire

Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress

12 May 2022 07:00:00 By Nasdaq GlobeNewswire

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022

10 May 2022 04:00:05 By Nasdaq GlobeNewswire

Agios Reports Business Highlights and First Quarter 2022 Financial Results

05 May 2022 04:00:03 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022

21 Apr 2022 04:00:01 By Nasdaq GlobeNewswire

Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency

14 Apr 2022 05:34:52 By Nasdaq GlobeNewswire

Agios to Participate in March Investor Conferences

28 Feb 2022 04:00:01 By Nasdaq GlobeNewswire

Agios Reports Fourth Quarter and Full Year 2021 Financial Results

24 Feb 2022 04:00:03 By Nasdaq GlobeNewswire

Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

17 Feb 2022 12:41:11 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Fourth Quarter and Year End 2021 Financial Results on Feb. 24, 2022

10 Feb 2022 04:00:01 By Nasdaq GlobeNewswire

Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Company’s Strategic Vision in Genetically Defined Diseases

10 Jan 2022 04:00:02 By Nasdaq GlobeNewswire

Agios to Present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

22 Dec 2021 04:00:00 By Nasdaq GlobeNewswire